✦ LIBER ✦

Efficacy and Safety of the Platelet-Activating Factor Receptor Antagonist BN 52021 (Ginkgolide B) in Patients with Severe Sepsis

✍ Scribed by Prof. Dr med. D. M. Albrecht, K. van Ackern, H. -J. Bender, H. Hof, W. Kox, N. Victor, P. Funk, M. Kieser, S. Köhler, D. Krausch, I. Marzi, T. Menges, H. Schmidt

Book ID: 119929904
Publisher: Springer International Publishing AG
Year: 2004
Tongue: English
Weight: 143 KB
Volume: 24
Category: Article
ISSN: 1179-1918
DOI: 10.2165/00044011-200424030-00002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cellular electrophysiological effects of

Cellular electrophysiological effects of the platelet activating factor antagonist BN 52021 (ginkgolide B) during myocardial ischaemia and reperfusion

✍ Nicholas A. Flores; Desmond J. Sheridan 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 96 KB

Bleomycin-Induced Lung Injury in the Rat

Bleomycin-Induced Lung Injury in the Rat: Effects of the Platelet-Activating Factor (PAF) Receptor Antagonist BN 52021 and Platelet Depletion

✍ Timothy W. Evans, Robin J. McAnulty, Duncan F. Rogers, K. Fan Chung, Peter J. Ba 📂 Article 📅 1990 🏛 Environmental Health Information Service 🌐 English ⚖ 939 KB

Role of PAF-acether in the mediation of

Role of PAF-acether in the mediation of pathophysiological responses to aggregated immunoglobulins. Studies with the platelet-activating factor receptor antagonist BN 52021

✍ Sagrario Fernandez-Gallardo; Ernesto Cano; Pierre Braquet; Mariano Sanchez Cresp 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 599 KB

Proof of the involvement of platelet act

Proof of the involvement of platelet activating factor (Paf-acether) in pulmonary complex immune systems using a specific Paf-acether receptor antagonist: BN 52021

✍ C. Touvar; B. Vilain; J.E. Taylor; A. Etienne; P. Braquet 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 695 KB

The safety and efficacy of B-domain dele

The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update

✍ J. M. Lusher; D. A. Roth 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 29 KB

Clinical efficacy, safety and pharmacoki

Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine® in previously treated patients with severe haemophilia B

✍ M. SERBAN; A. B. SKOTNICKI; M. COLOVIC; C. JINCA; A. KLUKOWSKA; P. LAGUNA; D. M. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB